A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market
5 Articles
5 Articles
A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market
Markets Key Facts —The move. Brazil’s Hypera filed to launch Semavy, its own semaglutide pen. —The rival. It targets the same drug class as Novo Nordisk’s Ozempic. —The market. Semaglutide moves at least R$5bn ($960m) a year in Brazil. —The trigger. Semaglutide’s Brazilian patent expired in March 2026. —The first. Rival EMS already won approval […] The post A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market appeared first on The …
The request for price analysis of the medicine with semaglutide of Cosmed, subsidiary of Hypera, arrived on Tuesday (23) to the Chamber of Regulation of the Market of Medicines (CMED). According to the panel of the organ, the new Brazilian analogue of the Ozempic, the antidiabetic pen of the Danish manufacturer Novo Nordisk, is called Semavy and follows under analysis of Anvisa, the Brazilian regulatory agency. Read more: National groups can hav…
A new medicine containing synthetic Semaglutide — used in slimming pens — is due to arrive in Brazil this year. The product has been named Semavy, and will be distributed by the pharmacist Hypera Pharma. According to Hypera Pharma, for the production and distribution of the pen, it is still necessary to register the technical record of Anvisa. Hypera Pharma informs that it has approved, with the Chamber of Regulation of the Market for Medicinal …
Folha de S.Paulo
UOLThe second medicine of the national industry containing semaglutide synttica j has name. It is Semavy, pen injection vel manufactured by the pharmaceutical Hypera Pharma. Read more (06/24/2026
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
